FDA Accepts sBLA for Priority Review of Dupilumab for Uncont

The FDA’s decision is planned for June 2024, and follows the successful results of the BOREAS and NOTUS trials.

Related Keywords

, Drug Administration , Biologics License Application , Priority Review , Esbla , Fda , Copd , Uncontrolled , Pulmonary , Dupilumab , Dupixent ,